https://www.selleckchem.com/pr....oducts/almorexant-hc
009) and for FLTi EVS, EFS for sensitive/resistant was 52 ± 8%/5 ± 5% (p less then 0.001). Seventeen patients were both inhibited and sensitive, with an EFS of 88 ± 8%. Adding lestaurtinib did not improve EFS overall, but patients achieving potent FLT3 inhibition and those whose leukemia blasts were sensitive FLT3-inhibition ex vivo did benefit from the addition of lestaurtinib. Patient selection and PD-guided dose escalation may enhance the efficacy of FLT3 inhibition for KMT2A-r infant ALL.Interferon regulatory factor 4 (IRF4
Like
Comment
Share
